Malignant Neoplasms of Urinary Tract
7
1
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
29%
2 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Oral Supplementation to Enhance Recovery Pilot Study
Neuromuscular Blockade on Shoulder Pain of Elderly
Investigation of Sugammadex in Outpatient Urological Procedures
Lenvatinib and Capecitabine in Patients With Advanced Malignancies